High blood pressure means your blood pushes too hard on your blood vessel walls all the time. Almost half of all adults in the U.S. have it. It can lead to heart attack, stroke, and kidney disease. Most people feel no symptoms at all. That is why getting your blood pressure checked matters. Treatment includes healthy habits and medicine, and most people need both for life.
High blood pressure — also called hypertension — means your blood pressure stays too high over time. It affects nearly half of U.S. adults. It is one of the top risk factors that can be changed for heart attack, stroke, and kidney disease. Most people have no warning signs, which is why regular blood pressure checks are so important. Treatment combines healthy lifestyle changes and medication, and for most people it continues for the rest of their life.
Hypertension — persistently elevated blood pressure — affects nearly half of U.S. adults and is one of the leading modifiable risk factors for heart attack, stroke, and kidney disease. Most people have no symptoms, which is why routine measurement matters. Management combines lifestyle modification and medication, and for most people it is lifelong.
Hypertension — persistently elevated arterial blood pressure — affects approximately half of U.S. adults and ranks among the leading modifiable risk factors for myocardial infarction, stroke, and chronic kidney disease. The condition is largely asymptomatic, underscoring the importance of routine screening. Management integrates lifestyle modification with pharmacotherapy and is, for the majority of patients, a lifelong undertaking.
Hypertension, defined by persistently elevated systemic arterial pressure, has a prevalence approaching 50% among U.S. adults and constitutes one of the most significant modifiable contributors to atherosclerotic cardiovascular disease, cerebrovascular events, and hypertensive nephropathy. Its characteristically asymptomatic course necessitates population-level screening programs for early identification. Optimal management requires sustained integration of evidence-based lifestyle interventions and antihypertensive pharmacotherapy, with the understanding that treatment is indefinite for the vast majority of affected individuals.
This is a synthesized view — not a replacement for your care team.
High blood pressure treatment is different for each person. Your blood pressure goal, the medicines your doctor suggests, and how often you come in for visits all depend on your heart health, kidney health, and other health problems you may have. The plan below follows trusted guidelines from heart doctor groups called the AHA and ACC. Your own care team will adjust that plan to fit you.
Managing high blood pressure looks different from person to person. Your blood pressure target, the medications your clinician recommends, and how often you need follow-up visits all depend on your overall heart risk, kidney function, and any other health conditions. The steps below follow current guidelines from the AHA and ACC — two leading heart health organizations. Your care team will tailor that plan to your specific situation.
Hypertension management is individualized. Your blood pressure target, the medications your clinician recommends, and the timeline for follow-up depend on your overall cardiovascular risk, kidney function, and other health conditions. The roadmap below reflects current consensus from AHA/ACC guidelines; your care team will adapt it to your specific situation.
Hypertension management is individualized. Blood pressure targets, recommended pharmacologic agents, and follow-up intervals are determined by a patient's overall cardiovascular risk profile, renal function, and comorbid conditions. The roadmap below reflects current consensus from AHA/ACC guidelines; the treating clinician will adapt these recommendations to the patient's specific clinical context.
Antihypertensive management is inherently patient-specific, with blood pressure targets, drug selection, and follow-up schedules calibrated to individual cardiovascular risk stratification, estimated glomerular filtration rate, and relevant comorbidities. The framework presented here is grounded in current AHA/ACC consensus guidelines; clinical application requires individualized modification based on the patient's comprehensive risk-benefit profile.
01 / Roadmap
Your first two years, mapped out.
A structured path from diagnosis through the choices that come next — so you have one place to look instead of three websites and four phone calls.
01
Week 0–2•You are here
Confirm the diagnosis and understand your numbers.
One high reading does not mean you have high blood pressure for sure. Your doctor will check your blood pressure several times to be sure. Sometimes they will ask you to measure it at home or wear a special monitor for 24 hours. This step is about getting the right numbers first — not about starting medicine right away.
One high blood pressure reading is not enough to diagnose hypertension. Your clinician will confirm the diagnosis by measuring your blood pressure several times. They may also ask you to check it at home or use a 24-hour monitor that you wear throughout the day and night. This first step is about getting accurate baseline numbers — not about starting medication straight away.
A single elevated reading is not enough to diagnose hypertension. Your clinician will confirm the diagnosis with repeated measurements — sometimes including home monitoring or a 24-hour ambulatory blood pressure study. This initial window is about getting accurate baseline numbers, not starting medications immediately.
A single elevated blood pressure reading is insufficient to establish a diagnosis of hypertension. Confirmation requires repeated measurements, which may include home blood pressure monitoring or 24-hour ambulatory blood pressure monitoring (ABPM). This initial phase focuses on obtaining reliable baseline data rather than initiating pharmacotherapy.
A solitary elevated blood pressure recording is diagnostically insufficient for hypertension. Confirmation requires serial measurements, potentially supplemented by home blood pressure monitoring or 24-hour ambulatory blood pressure monitoring (ABPM) to exclude white-coat hypertension and characterize circadian pressure patterns. This diagnostic phase prioritizes establishment of accurate baseline hemodynamic data before any therapeutic decision is made.
Learn your target BPAsk about home monitoringList your current medications
02
Week 2–6
Complete your cardiovascular risk assessment.
High blood pressure often comes with other health problems. Your doctor will probably do blood tests to check your kidneys, blood sugar, salt levels, and cholesterol. They may also do a heart tracing called an ECG and check your urine. They will also look at your chance of having a heart problem in the next 10 years. All of these results help your doctor decide how hard to work to lower your blood pressure and whether you need medicine.
High blood pressure rarely exists on its own. Your care team will likely run blood tests to check kidney function, electrolytes, fasting blood sugar, and cholesterol. They may also do an ECG — a quick test that records your heart's electrical activity — and check a urine sample. They will also estimate your overall risk of a heart problem over the next 10 years. All of this information shapes how aggressively your blood pressure will be treated and whether medication makes sense alongside lifestyle changes.
Hypertension rarely exists alone. Your team will likely check labs — kidney function, electrolytes, fasting glucose, and a lipid panel — and review your overall 10-year cardiovascular risk. An ECG and urinalysis are also common. These results shape how aggressively blood pressure will be treated and whether medication is recommended alongside lifestyle changes.
Hypertension frequently coexists with other cardiovascular risk factors and end-organ effects. Workup typically includes laboratory assessment of renal function, electrolytes, fasting glucose, and a fasting lipid panel, along with an ECG and urinalysis. Calculation of 10-year cardiovascular risk informs the intensity of blood pressure management and guides the decision to initiate antihypertensive medication concurrently with lifestyle modification.
Hypertension infrequently presents in isolation; comprehensive evaluation includes laboratory assessment of renal function (serum creatinine, estimated GFR), electrolytes, fasting glucose, and a fasting lipid panel, complemented by ECG and urinalysis to detect early target-organ involvement. Pooled Cohort Equations-based 10-year atherosclerotic cardiovascular disease (ASCVD) risk stratification directly informs treatment intensity thresholds and the decision regarding concurrent pharmacotherapy initiation alongside structured lifestyle intervention.
What labs to expectAsk about your cardiovascular risk scoreQuestions to bring
03
Month 1–3
Start lifestyle changes and, if indicated, medication.
If you have stage 1 high blood pressure and your heart risk is not high, your doctor may ask you to try healthy lifestyle changes first before starting medicine. These include eating the DASH diet, using less salt, being more active, and drinking less alcohol. If you have stage 2 high blood pressure or your heart risk is high, guidelines say it is better to start medicine and make lifestyle changes at the same time — not wait.
For stage 1 hypertension without high cardiovascular risk, starting with structured lifestyle changes is often the first step. This includes following the DASH diet, cutting back on sodium, getting more physical activity, and limiting alcohol. For stage 2 hypertension or patients with high heart risk, guideline recommendations support starting antihypertensive medication at the same time as lifestyle changes rather than waiting to see if lifestyle changes alone are enough.
For stage 1 hypertension without high cardiovascular risk, a trial of structured lifestyle modification — including the DASH diet, sodium reduction, increased physical activity, and limiting alcohol — is often the first step. For stage 2 hypertension or high-risk patients, guideline consensus supports starting antihypertensive medication at the same time as lifestyle changes rather than waiting.
For stage 1 hypertension in the absence of high cardiovascular risk, a time-limited trial of structured lifestyle modification — encompassing the DASH diet, sodium restriction, increased aerobic activity, and alcohol limitation — is the recommended initial approach. In contrast, stage 2 hypertension or the presence of high cardiovascular risk warrants simultaneous initiation of antihypertensive pharmacotherapy and lifestyle intervention, per current guideline consensus.
For stage 1 hypertension without elevated cardiovascular risk, current guideline consensus supports a structured trial of lifestyle modification — including the DASH dietary pattern, sodium restriction, aerobic exercise, and alcohol limitation — as first-line management. For stage 2 hypertension or patients with high ASCVD risk, guidelines recommend concurrent initiation of antihypertensive pharmacotherapy and lifestyle intervention, foregoing a watchful-waiting period, to achieve timely blood pressure reduction and mitigate cardiovascular event risk.
DASH diet overviewSodium reduction tipsAsk about medication options
04
Month 3–6
Assess response and adjust the regimen.
About 4 to 6 weeks after starting medicine, you will have a follow-up visit. Your doctor will check whether your blood pressure is reaching the right target. Many people need more than one medicine to get there. At this stage, your doctor may change your dose, switch to a different type of medicine if you are having side effects, or add a second medicine.
About 4 to 6 weeks after starting medication, you will have a follow-up visit to see if your blood pressure is reaching the target. Many people need more than one medication to reach their goal. This phase is about fine-tuning — adjusting doses, switching to a different drug class if side effects are a problem, or adding a second medication.
A follow-up visit at roughly 4–6 weeks after starting medication checks whether your blood pressure is reaching target. Many people need more than one medication to reach goal. This phase is about fine-tuning — adjusting doses, switching drug classes if side effects occur, or adding a second agent.
A follow-up visit approximately 4–6 weeks after treatment initiation assesses whether blood pressure is approaching target. Pharmacologic management frequently requires combination therapy; this phase involves dose titration, substitution of an alternative drug class when adverse effects are intolerable, or addition of a second antihypertensive agent to achieve goal blood pressure.
A follow-up assessment at approximately 4–6 weeks post-initiation evaluates therapeutic response and tolerability. Given that a substantial proportion of patients require combination antihypertensive therapy to achieve target blood pressure, this phase involves systematic dose optimization, class substitution for adverse-effect management, or the addition of a complementary-mechanism agent. Drug selection in combination regimens is guided by evidence-based pairing strategies and patient-specific comorbidities.
Track your readings at homeReport side effects promptlyAsk about combination pills
05
Month 6–12
Stabilize and establish your long-term routine.
Once your blood pressure is at the right level and stays there, visits usually happen every 3 to 6 months. You will also have blood tests once a year to check your kidneys and salt levels. This is especially important if you take certain medicines called ACE inhibitors, ARBs, or diuretics (water pills). The goal is to keep taking your medicine and healthy habits and to catch any early problems with your heart, kidneys, or eyes.
Once your blood pressure is consistently at goal, visits usually shift to every 3 to 6 months. Annual blood tests monitor kidney function and electrolytes — this is especially important if you take ACE inhibitors, ARBs, or diuretics. The focus during this phase is staying consistent with your medications and habits and catching any early signs that high blood pressure may be affecting your heart, kidneys, or eyes.
Once blood pressure is consistently at goal, visits typically move to every 3–6 months. Annual labs monitor kidney function and electrolytes, particularly with ACE inhibitors, ARBs, or diuretics. The goal in this phase is maintaining consistent adherence and catching any early signs of target organ involvement — heart, kidney, or eyes.
Once blood pressure is consistently at target, follow-up intervals typically extend to every 3–6 months. Annual laboratory monitoring of renal function and electrolytes is standard, particularly for patients on ACE inhibitors, ARBs, or diuretics given their renal and electrolyte effects. The primary objectives in this maintenance phase are sustaining medication adherence and detecting early target-organ involvement affecting the heart, kidneys, or retina.
With sustained blood pressure at goal, follow-up frequency is appropriately reduced to every 3–6 months. Annual surveillance labs — serum creatinine, estimated GFR, and electrolytes — are indicated, particularly in patients receiving renin-angiotensin-aldosterone system (RAAS) inhibitors or thiazide/thiazide-like diuretics, given their respective nephrotoxic and electrolyte-dysregulation risk profiles. The maintenance phase prioritizes long-term adherence optimization and surveillance for subclinical target-organ damage involving the myocardium, renal parenchyma, and hypertensive retinopathy.
Surveillance scheduleMedication refill planningWhen to call your doctor
06
Ongoing
Lifelong management — with fewer surprises over time.
High blood pressure is a lifelong condition. Sticking with your medicine and healthy habits over time is what keeps you from getting serious problems. Most people whose blood pressure is well controlled live full and active lives. Your doctor will check in with you over time — especially if your weight, kidneys, or other health issues change — to make sure your treatment still fits your needs.
Hypertension is a long-term condition, and keeping up with medication and lifestyle changes over time is what prevents complications. Most people with well-controlled blood pressure live full, active lives. Periodic reassessment — especially if your weight, kidney function, or other health conditions change — helps make sure your treatment plan continues to match your needs.
Hypertension is a chronic condition, and long-term adherence to medication and lifestyle changes is what prevents complications. Most people with well-controlled blood pressure live full, active lives. Periodic reassessment — especially if weight, kidney function, or other health conditions change — keeps the regimen matched to your needs.
Hypertension is a chronic condition requiring indefinite adherence to both pharmacotherapy and lifestyle modification to prevent major complications. Most patients with consistently controlled blood pressure maintain good functional status and quality of life. Ongoing reassessment, particularly in the context of significant changes in weight, renal function, or comorbidities, ensures the treatment regimen remains appropriately calibrated.
As a chronic condition, hypertension mandates sustained adherence to antihypertensive pharmacotherapy and evidence-based lifestyle modification to prevent cardiovascular, cerebrovascular, and renal complications. The majority of patients achieving consistent blood pressure control maintain excellent functional capacity and health-related quality of life. Long-term management requires periodic reassessment of the pharmacologic regimen in response to clinically significant changes in body weight, renal function, comorbidity burden, or emerging drug-drug interactions.
Starting with the question most people care about most: what changes about real life. Harder topics are below, available when (and only when) you want them.
a
Day-to-day routines
For most people, well-controlled high blood pressure does not cause any symptoms from day to day. The main change in your routine is remembering to take a pill each day and checking your blood pressure at home from time to time. Healthy habits — like eating better, moving more, and using less salt — become a regular part of life rather than something you do for a short time.
For most people, well-controlled hypertension causes no noticeable symptoms day to day. The main routine change is remembering to take a once-daily pill and checking your blood pressure at home periodically. Lifestyle adjustments — such as diet, physical activity, and sodium intake — become ongoing habits rather than short-term fixes.
For most people, well-controlled hypertension produces no noticeable symptoms day to day. The main routine change is remembering to take a once-daily pill and periodically checking blood pressure at home. Lifestyle adjustments — diet, activity, sodium intake — become ongoing habits rather than short-term interventions.
Well-controlled hypertension is largely asymptomatic in daily life. The primary routine change involves adherence to a once-daily antihypertensive medication and periodic home blood pressure monitoring. Lifestyle modifications — including dietary adjustment, regular physical activity, and sodium restriction — are maintained as long-term behavioral habits rather than time-limited interventions.
Adequately controlled hypertension is characteristically asymptomatic, imparting minimal day-to-day functional burden. The principal behavioral demands are sustained pharmacologic adherence, typically to a once-daily regimen, and periodic home blood pressure surveillance. Evidence-based lifestyle modifications — including the DASH dietary pattern, aerobic exercise, and sodium restriction — must be maintained indefinitely as independent antihypertensive interventions rather than adjunctive or time-limited measures.
b
Work and energy
High blood pressure itself does not usually make you tired or limit what you can do at work, especially when it is controlled. Some blood pressure medicines can cause dizziness or tiredness when you first start taking them or when your dose goes up. These effects usually get better after a few weeks. If they do not get better, your doctor can change your medicine.
Hypertension itself does not typically limit your energy or ability to work, especially when blood pressure is under control. Some antihypertensive medications can cause dizziness or fatigue early on — particularly when starting or increasing a dose. These effects usually improve within a few weeks. If they do not, your clinician can adjust your regimen.
Hypertension itself does not typically limit work capacity or energy, particularly when blood pressure is controlled. Some antihypertensive medications can cause dizziness or fatigue early in treatment, especially when starting or increasing doses. These effects usually improve over a few weeks; if they persist, your clinician can adjust the regimen.
Hypertension itself does not typically impair work capacity or energy levels, particularly when blood pressure is adequately controlled. Some antihypertensive agents may produce dizziness or fatigue during treatment initiation or dose escalation. These adverse effects generally resolve within a few weeks; persistent symptoms warrant a regimen adjustment by the treating clinician.
Hypertension per se does not typically compromise functional capacity or occupational performance when blood pressure is therapeutically controlled. Initiation or up-titration of antihypertensive agents — particularly vasodilators and agents with negative chronotropic or inotropic properties — may transiently induce orthostatic hypotension, dizziness, or fatigue. These adverse effects are generally self-limiting over several weeks; persistence should prompt pharmacologic reassessment, including dose adjustment or drug-class substitution.
c
Family and hereditary risk
High blood pressure runs in families. If someone in your close family has it, you have a higher chance of getting it too. There is no single gene test that can tell if you will get it. But knowing you have it is a useful signal for your close relatives — brothers, sisters, parents, and children. Tell them so they can get their own blood pressure checked more often and catch any problems early.
High blood pressure has a strong family component. First-degree relatives — parents, siblings, and children — of someone with hypertension have a meaningfully higher risk of developing it themselves. There is no single genetic test that predicts it, but a diagnosis in the family is a practical signal for close relatives to monitor their own blood pressure regularly. Sharing your diagnosis can help others catch it earlier.
Hypertension has a strong familial component — first-degree relatives of someone with hypertension have meaningfully higher risk. There is no single gene test that predicts it, but the diagnosis is a practical signal for family members to monitor their own blood pressure regularly. Sharing your diagnosis with close relatives allows earlier detection on their end.
Hypertension has a significant heritable component — first-degree relatives of an affected individual carry meaningfully elevated risk. No single genetic test reliably predicts hypertension, but a family diagnosis serves as a clinically actionable prompt for relatives to establish regular blood pressure monitoring. Early identification in at-risk family members facilitates timely intervention.
Hypertension demonstrates substantial heritability, with first-degree relatives of affected probands carrying significantly elevated risk attributable to polygenic predisposition and shared environmental exposures. No single-gene diagnostic test currently offers clinically reliable predictive utility for essential hypertension. Nevertheless, a family diagnosis constitutes a pragmatic epidemiologic signal warranting routine blood pressure surveillance among first-degree relatives to facilitate early detection and pre-hypertensive intervention.
d
Mental load
Being told you have high blood pressure can be stressful. This is true even though you may not have felt any symptoms. Needing to take medicine for the rest of your life can feel like a lot. Worrying about stroke or heart attack is common. Stress can also raise your blood pressure for a short time, and long-term stress is known to be linked to high blood pressure. Taking care of your mental health is an important part of taking care of your heart.
A hypertension diagnosis can be unexpectedly stressful — especially because it often comes without any warning symptoms and means taking medication indefinitely. Feeling anxious about stroke or heart attack risk is common. Stress can temporarily raise blood pressure, and the connection between ongoing stress and hypertension is well recognized. Taking care of your mental health is a practical and evidence-supported part of your overall heart health care.
A hypertension diagnosis can be unexpectedly stressful, particularly because it arrives without warning symptoms and requires indefinite medication. Anxiety about stroke or heart attack risk is common. Stress itself can temporarily raise blood pressure, and the relationship between chronic stress and hypertension is well recognized in the literature. Addressing mental health as part of overall cardiovascular care is both practical and evidence-informed.
A hypertension diagnosis can be psychologically distressing, particularly given its asymptomatic onset and the prospect of indefinite pharmacotherapy. Anxiety about stroke and myocardial infarction risk is common among newly diagnosed patients. Acute stress transiently elevates blood pressure, and the association between chronic psychosocial stress and sustained hypertension is well documented. Integrating mental health support into cardiovascular care is both clinically practical and evidence-informed.
Hypertension diagnosis frequently engenders significant psychological distress, compounded by its asymptomatic presentation and the requirement for lifelong pharmacologic management. Anxiety regarding stroke and myocardial infarction risk is prevalent in newly diagnosed patients. Acute sympathoadrenal activation transiently elevates arterial pressure, while the association between chronic psychosocial stress, hypothalamic-pituitary-adrenal axis dysregulation, and sustained hypertension is well established in the literature. Incorporating mental health assessment and intervention into the cardiovascular risk management framework is supported by evidence and clinical practice recommendations.
e
Diet, activity, and lifestyle
Changing your lifestyle is not just a side note to taking medicine — it is a real treatment on its own that can lower your blood pressure. The DASH diet focuses on eating more fruits, vegetables, and low-fat dairy and less salt and saturated fat. Regular exercise, drinking less alcohol, and not smoking all help lower blood pressure in important ways. The DASH diet was tested in a careful study called the DASH trial, which showed it really works.
Lifestyle changes are not just a footnote to medication — they are a real treatment that can lower blood pressure on their own. The DASH diet — which emphasizes fruits, vegetables, and low-fat dairy and limits sodium and saturated fat — regular aerobic exercise, limiting alcohol, and avoiding tobacco all meaningfully help control blood pressure. The DASH trial was a rigorous randomized study that established the diet's effectiveness.
Lifestyle modification is not a footnote to medication — it is an independent treatment with demonstrated blood pressure-lowering effects. The DASH diet (rich in fruits, vegetables, and low-fat dairy; low in sodium and saturated fat), regular aerobic exercise, limiting alcohol, and avoiding tobacco all contribute meaningfully to blood pressure control. The DASH trial established the dietary approach's effectiveness in a rigorous randomized trial.
Lifestyle modification is an independent, evidence-based antihypertensive intervention, not merely an adjunct to pharmacotherapy. The DASH diet — characterized by high intake of fruits, vegetables, and low-fat dairy and restricted sodium and saturated fat — combined with regular aerobic exercise, alcohol limitation, and tobacco avoidance, produces clinically meaningful blood pressure reductions. The effectiveness of the DASH dietary pattern was established in the DASH trial, a rigorous randomized controlled trial.
Lifestyle modification constitutes an independent, evidence-graded antihypertensive intervention with quantifiable blood pressure-lowering efficacy. The DASH dietary pattern — defined by high fruit, vegetable, and low-fat dairy intake with concomitant restriction of dietary sodium and saturated fat — along with structured aerobic exercise, alcohol restriction, and tobacco cessation, each independently and additively contribute to blood pressure reduction. The DASH trial, a rigorous randomized controlled feeding study, prospectively established the dietary pattern's antihypertensive efficacy and provided the evidentiary basis for its incorporation as a primary non-pharmacologic strategy in AHA/ACC hypertension guidelines.
f
The visits themselves
High blood pressure care is usually handled by your regular doctor. If your blood pressure is hard to control, or if you have kidney disease or heart problems, a heart specialist (cardiologist) or kidney specialist (nephrologist) may also help with your care. Once your medicines are working well, visits are usually short — your doctor will check your blood pressure, go over your medicines, and review any recent blood tests. Checking your blood pressure at home between visits is a good idea and helps your doctor see the full picture.
Hypertension is usually managed by a primary care clinician. A cardiologist — a heart specialist — or a nephrologist — a kidney specialist — may get involved if blood pressure is hard to control or if heart or kidney complications develop. Once your regimen is stable, visits are usually brief and focused on blood pressure measurement, reviewing medications, and going over lab results. Checking your blood pressure at home between visits is increasingly recommended and gives your clinician more information than office readings alone.
Hypertension care is typically managed by a primary care clinician, though a cardiologist or nephrologist may be involved if blood pressure is difficult to control or if kidney disease or heart complications develop. Visits are usually brief once the regimen is stable — focused on blood pressure measurement, medication review, and periodic lab results. Home blood pressure monitoring between visits is increasingly recommended and gives your clinician a fuller picture than office readings alone.
Hypertension is primarily managed in primary care, though cardiology or nephrology referral is warranted when blood pressure is resistant to treatment or when cardiac or renal complications arise. Once the regimen is stable, clinic visits are brief — focused on blood pressure measurement, medication review, and interval lab results. Home blood pressure monitoring is increasingly recommended as a complement to office readings, providing a more comprehensive hemodynamic profile.
Hypertension management is predominantly within the scope of primary care, with cardiology or nephrology involvement indicated in cases of resistant hypertension, complex cardiovascular comorbidity, or progressive hypertensive nephropathy. Following regimen stabilization, ambulatory visits are appropriately abbreviated, centering on blood pressure assessment, pharmacologic review, and surveillance laboratory results. Out-of-office blood pressure monitoring — including home blood pressure monitoring (HBPM) and, when indicated, 24-hour ambulatory blood pressure monitoring (ABPM) — is increasingly endorsed by guidelines as a superior method of hemodynamic assessment compared to isolated office sphygmomanometry.
⚠ Sensitive content — long-term risk and complications
When high blood pressure is not treated or not controlled, it can cause serious problems. These include stroke, heart attack, heart failure, kidney disease, and damage to the blood vessels in the eyes (called hypertensive retinopathy). The higher your blood pressure, the higher your risk — there is no level where risk completely disappears. But with steady treatment, most of these risks go down a lot. A large study called the SPRINT trial found that aiming for a systolic blood pressure (the top number) below 120 mmHg lowered the chance of serious heart problems more than aiming for below 140 mmHg — but this stricter goal is not right for everyone. Statistics from studies are about groups of people, not a prediction for any one person.
Uncontrolled hypertension is a major risk factor for stroke, heart attack, heart failure, chronic kidney disease, and damage to the blood vessels in the eyes — called hypertensive retinopathy. The relationship between blood pressure and cardiovascular risk is continuous — risk increases steadily as blood pressure rises, and there is no sharp cutoff below which risk vanishes entirely. With consistent treatment, most of these risks are substantially reduced. The SPRINT trial found that targeting a systolic blood pressure — the top number — below 120 mmHg reduced major cardiovascular events compared to a target below 140 mmHg in a high-risk group, though that more intensive goal is not recommended for everyone. Population statistics describe averages across groups — they are not predictions for any individual person.
Uncontrolled hypertension is a major risk factor for stroke, myocardial infarction, heart failure, chronic kidney disease, and hypertensive retinopathy. The relationship between blood pressure and cardiovascular events is continuous — risk rises incrementally with higher readings, with no sharp threshold below which risk disappears entirely. With consistent treatment, most of these risks are substantially reduced. The SPRINT trial demonstrated that targeting systolic blood pressure below 120 mmHg lowered rates of major cardiovascular events compared to a target below 140 mmHg in a high-risk population, though that more intensive target is not recommended for everyone. Population-level statistics describe averages across groups; they are not predictions for any individual person.
Uncontrolled hypertension is a leading risk factor for stroke, myocardial infarction, heart failure, chronic kidney disease, and hypertensive retinopathy. The association between blood pressure elevation and cardiovascular risk is continuous and graded — there is no threshold below which residual risk is entirely absent. Consistent antihypertensive treatment substantially reduces most of these risks. The SPRINT trial demonstrated that targeting a systolic blood pressure below 120 mmHg significantly reduced major cardiovascular events compared to a target below 140 mmHg in a high-risk, non-diabetic population; however, this intensive target is not universally applicable. Population-level statistics reflect group averages and do not constitute individualized risk predictions.
Uncontrolled hypertension is a major independent risk factor for ischemic and hemorrhagic stroke, myocardial infarction, heart failure, hypertensive nephropathy, and hypertensive retinopathy. The relationship between arterial pressure and cardiovascular event risk is continuous and log-linear — incremental pressure increases confer proportionally greater risk with no demonstrable lower threshold of zero residual risk. Sustained antihypertensive therapy substantially attenuates these risks across endpoints. The SPRINT trial demonstrated that an intensive systolic blood pressure target of less than 120 mmHg significantly reduced the composite of major adverse cardiovascular events and all-cause mortality compared to a standard target of less than 140 mmHg in high-risk, non-diabetic adults; however, generalizability of this intensive target is limited by patient selection criteria and should be individualized. Epidemiologic statistics characterize population-level risk distributions and are not deterministic for individual patients.
These numbers describe populations, not individuals. Your clinician can put them in context of your specific cardiovascular risk profile.
03 / Medications
Treatments, standard and emerging.
Common medications people are typically on, plus newer therapies you may hear about. Tap any card to save it to your dashboard.
Lisinopril
lisinopril, ramipril, enalapril, benazepril
Standard
Lisinopril belongs to a group of medicines called ACE inhibitors. ACE inhibitors block a protein in the body called angiotensin-converting enzyme. This stops a signal that squeezes your blood vessels and raises blood pressure. Other medicines in this group include ramipril, enalapril, and benazepril. ACE inhibitors are one of the first medicines doctors reach for to treat high blood pressure. They are especially helpful for people with diabetes or early kidney disease. Many big studies have shown they are good for heart health.
Lisinopril is an ACE inhibitor — a drug that blocks an enzyme called angiotensin-converting enzyme, which would otherwise send a signal to tighten blood vessels and raise blood pressure. Other ACE inhibitors include ramipril, enalapril, and benazepril. This class is a first-line option for treating hypertension and is particularly favored for people with diabetes or early kidney disease. Multiple landmark trials have shown strong cardiovascular benefits with ACE inhibitors.
Lisinopril belongs to the ACE inhibitor class — drugs that block angiotensin-converting enzyme, reducing the hormonal signal that constricts blood vessels and raises blood pressure. This class, which also includes ramipril, enalapril, and benazepril, is a first-line option for hypertension and is particularly favored in patients with diabetes or early kidney disease. ACE inhibitors have strong cardiovascular outcome data from multiple landmark trials.
Lisinopril is an ACE inhibitor, a drug class that blocks angiotensin-converting enzyme and thereby reduces angiotensin II-mediated vasoconstriction and aldosterone release, lowering blood pressure. The class includes ramipril, enalapril, and benazepril. ACE inhibitors are a first-line antihypertensive option, with particular indication in patients with diabetes or early chronic kidney disease. The class has robust cardiovascular outcome data from multiple landmark trials.
Lisinopril is an ACE inhibitor that competitively inhibits angiotensin-converting enzyme, reducing conversion of angiotensin I to angiotensin II and thereby attenuating angiotensin II-mediated vasoconstriction, aldosterone secretion, and sympathetic activation. The class — which includes ramipril, enalapril, and benazepril — is a guideline-recommended first-line antihypertensive, with preferred indication in patients with diabetic nephropathy or early hypertensive chronic kidney disease given its established renoprotective and cardiovascular risk-reduction profiles across multiple large-scale randomized outcome trials.
FormOral
FrequencyOnce daily
Approved1987–1996
OTCNo
From trialYes
Amlodipine
amlodipine, nifedipine, diltiazem
Standard
Amlodipine is a type of medicine called a calcium channel blocker. It works by relaxing the muscles in the walls of your blood vessels, which lowers the resistance in the vessels and brings down your blood pressure. Nifedipine and diltiazem are also in this group. Amlodipine is a first-choice medicine for high blood pressure. A major study called the ALLHAT trial showed it works well. You take it once a day and most people tolerate it easily.
Amlodipine is a calcium channel blocker — it works by relaxing the smooth muscle in blood vessel walls, reducing resistance in the vessels and lowering blood pressure. Nifedipine and diltiazem are also in this class. Amlodipine is a first-line option for hypertension with strong outcome data, including from the major ALLHAT trial. It is taken once daily and is generally well tolerated.
Amlodipine is a dihydropyridine calcium channel blocker that relaxes the smooth muscle in blood vessel walls, reducing vascular resistance and lowering blood pressure. Also in this class are nifedipine and diltiazem. Amlodipine is a first-line antihypertensive with strong outcome data — notably from the ALLHAT trial — and is widely used alone or in combination with other agents. It is taken once daily and is generally well tolerated.
Amlodipine is a dihydropyridine calcium channel blocker that inhibits L-type calcium channels in vascular smooth muscle, reducing vascular resistance and lowering blood pressure. The class includes nifedipine and diltiazem. Amlodipine is a first-line antihypertensive with strong cardiovascular outcome data — notably from the ALLHAT trial — and is widely used as monotherapy or in combination regimens. It is taken once daily and is generally well tolerated.
Amlodipine is a dihydropyridine-class calcium channel blocker that selectively inhibits voltage-gated L-type calcium channels in vascular smooth muscle, producing arterial vasodilation, reduced systemic vascular resistance, and blood pressure lowering. The dihydropyridine class includes nifedipine; diltiazem is a non-dihydropyridine calcium channel blocker with additional nodal effects. Amlodipine demonstrated non-inferiority to chlorthalidone and lisinopril for the primary endpoint of fatal coronary heart disease and nonfatal myocardial infarction in the ALLHAT trial, establishing its first-line antihypertensive status. It is administered once daily and is characterized by a favorable tolerability profile.
FormOral
FrequencyOnce daily
Approved1987–1995
OTCNo
From trialYes
Chlorthalidone
chlorthalidone, hydrochlorothiazide, indapamide
Standard
Chlorthalidone is a water pill (diuretic). It lowers blood pressure by telling the kidneys to hold on to less fluid. Less fluid in your body means less pressure in your blood vessels. Other medicines in this group include hydrochlorothiazide and indapamide. These medicines have been used for high blood pressure since the 1960s and have been shown in early big studies to reduce the risk of stroke and heart attack. Chlorthalidone was the water pill used in a major study called ALLHAT, and it did at least as well as newer medicines for most heart outcomes.
Chlorthalidone is a thiazide-like diuretic — a type of water pill that lowers blood pressure by reducing the amount of fluid the kidneys retain. This drug class, which also includes hydrochlorothiazide and indapamide, has been the backbone of hypertension treatment since the 1960s and has been shown in early landmark trials to significantly lower the risk of stroke and heart attack. Chlorthalidone was the diuretic used in the ALLHAT trial, where it performed at least as well as newer drug classes for most cardiovascular outcomes.
Chlorthalidone is a thiazide-like diuretic that lowers blood pressure by reducing the volume of fluid the kidneys retain. This drug class, which also includes hydrochlorothiazide and indapamide, has been the backbone of hypertension treatment since the 1960s and demonstrated significant reductions in stroke and heart attack risk in early landmark trials. Chlorthalidone specifically was the diuretic used in ALLHAT, where it performed at least as well as newer drug classes for most cardiovascular outcomes.
Chlorthalidone is a thiazide-like diuretic that lowers blood pressure primarily by reducing renal tubular sodium and water reabsorption, thereby decreasing intravascular volume. The class includes hydrochlorothiazide and indapamide. Thiazide-type diuretics have been central to antihypertensive therapy since the 1960s, with early landmark trials demonstrating significant reductions in stroke and myocardial infarction. Chlorthalidone was the diuretic comparator in ALLHAT, where it performed at least as well as newer drug classes for most cardiovascular endpoints.
Chlorthalidone is a thiazide-like diuretic that reduces blood pressure through inhibition of the Na⁺-Cl⁻ cotransporter in the distal convoluted tubule, reducing renal sodium and water reabsorption and decreasing intravascular volume; long-term blood pressure reduction also involves a vasodilatory component. The class — which includes hydrochlorothiazide and indapamide — has constituted a cornerstone of antihypertensive pharmacotherapy since the 1960s, with early MRFIT and VA Cooperative Study data demonstrating meaningful reductions in stroke and coronary events. In ALLHAT, chlorthalidone was the active comparator and demonstrated non-inferiority to amlodipine and lisinopril for the primary composite cardiovascular endpoint, reinforcing its guideline-recommended first-line status.
FormOral
FrequencyOnce daily
Approved1960–1981
OTCNo
From trialYes
Losartan
losartan, valsartan, olmesartan, irbesartan
Standard
Losartan belongs to a group of medicines called ARBs — angiotensin II receptor blockers. A hormone called angiotensin II can tighten your blood vessels and raise blood pressure. ARBs block the place in the body where this hormone tries to act. Other medicines in this group include valsartan, olmesartan, and irbesartan. ARBs are often used when someone cannot take ACE inhibitors — for example, because ACE inhibitors cause a lasting cough. ARBs protect the heart and kidneys in similar ways to ACE inhibitors. A study called ONTARGET compared ARB treatment to ACE inhibitor treatment in people with high heart risk.
Losartan is an ARB — an angiotensin II receptor blocker. Angiotensin II is a hormone that raises blood pressure by constricting blood vessels. ARBs block the receptor that angiotensin II binds to, rather than stopping the hormone from being made. Other ARBs include valsartan, olmesartan, and irbesartan. This class is often used as an alternative when patients cannot tolerate ACE inhibitors, particularly because of ACE inhibitor-related cough. ARBs offer similar cardiovascular and kidney protection to ACE inhibitors. The ONTARGET trial directly compared ARB therapy to ACE inhibitor therapy in high-risk patients.
Losartan belongs to the angiotensin II receptor blocker (ARB) class — agents that block the receptor for the blood-pressure-raising hormone angiotensin II rather than inhibiting its production. This class includes valsartan, olmesartan, and irbesartan. ARBs are often used as an alternative when patients cannot tolerate ACE inhibitors (particularly due to ACE inhibitor-associated cough) and carry similar cardiovascular and renal-protection profiles. The ONTARGET trial directly compared ARB therapy to ACE inhibitor therapy in a high-risk population.
Losartan is an angiotensin II receptor blocker (ARB) that competitively antagonizes the AT₁ receptor, blocking the vasoconstrictive and aldosterone-stimulating effects of angiotensin II without inhibiting its production. The class includes valsartan, olmesartan, and irbesartan. ARBs are used as an alternative when ACE inhibitor-associated cough or angioedema is intolerable, and carry comparable cardiovascular and renoprotective profiles. The ONTARGET trial directly compared ARB therapy (telmisartan) to ACE inhibitor therapy (ramipril) in a high-risk population.
Losartan is an ARB that selectively antagonizes the angiotensin II type 1 (AT₁) receptor, thereby blocking angiotensin II-mediated vasoconstriction, aldosterone release, and sympathetic activation without suppressing angiotensin-converting enzyme or accumulating bradykinin — the latter mechanism underlying ACE inhibitor-associated cough and angioedema. The class includes valsartan, olmesartan, and irbesartan. ARBs are guideline-supported alternatives to ACE inhibitors with equivalent cardiovascular and renoprotective outcome profiles. The ONTARGET trial prospectively compared telmisartan to ramipril in 25,620 high-cardiovascular-risk patients, establishing class equivalence for major cardiovascular endpoints and providing evidence against dual RAAS blockade.
FormOral
FrequencyOnce daily
Approved1995–2002
OTCNo
From trialYes
Metoprolol
metoprolol, atenolol, carvedilol, bisoprolol
Standard
Metoprolol belongs to a group of medicines called beta-blockers. It lowers blood pressure by slowing the heart rate and reducing how hard the heart pumps. Other beta-blockers used for high blood pressure include atenolol, carvedilol, and bisoprolol. For straightforward high blood pressure, beta-blockers are not usually the first choice based on current guidelines. But they are important when high blood pressure comes with heart failure, coronary artery disease (blocked heart arteries), or certain problems with heart rhythm. You take metoprolol once or twice a day depending on the form.
Metoprolol is a beta-1 selective beta-blocker — it reduces blood pressure by slowing the heart rate and decreasing the amount of blood the heart pumps out. Other beta-blockers used for hypertension include atenolol, carvedilol, and bisoprolol. For uncomplicated hypertension, beta-blockers are not typically the first-line choice per current guidelines. However, they are preferred when hypertension is accompanied by heart failure, coronary artery disease, or certain arrhythmias — abnormal heart rhythms. Depending on the formulation, metoprolol is taken once or twice daily.
Metoprolol is a beta-1 selective beta-blocker that reduces blood pressure by slowing heart rate and decreasing cardiac output. Other agents in this class used for hypertension include atenolol, carvedilol, and bisoprolol. Beta-blockers are not typically first-line for uncomplicated hypertension per current guidelines, but they are preferred or necessary when hypertension accompanies heart failure, coronary artery disease, or certain arrhythmias. They are taken once or twice daily depending on the formulation.
Metoprolol is a beta-1 selective beta-blocker that lowers blood pressure by reducing heart rate and cardiac output via competitive antagonism at cardiac β₁-adrenergic receptors. Other agents in this class used for hypertension include atenolol, carvedilol, and bisoprolol. Per current guidelines, beta-blockers are not first-line for uncomplicated hypertension, but are preferred or necessary when hypertension coexists with heart failure, coronary artery disease, or certain arrhythmias. Dosing frequency is once or twice daily depending on the formulation.
Metoprolol is a cardioselective β₁-adrenergic receptor antagonist that reduces blood pressure through negative chronotropy and negative inotropy, decreasing cardiac output. The beta-blocker class for hypertension includes atenolol, carvedilol (a non-selective β- and α₁-blocker), and bisoprolol. Current AHA/ACC guidelines do not support beta-blockers as preferred first-line agents for uncomplicated hypertension, reflecting data from ASCOT-BPLA and meta-analyses demonstrating inferior stroke reduction versus calcium channel blockers and RAAS inhibitors at equivalent blood pressure reduction. Beta-blockers retain a preferred or necessary indication when hypertension coexists with heart failure with reduced ejection fraction, stable ischemic heart disease, or rate-controlling arrhythmias.
FormOral
FrequencyOnce or twice daily
Approved1978–1997
OTCNo
From trialNo
Spironolactone
spironolactone, eplerenone
Standard
Spironolactone is a medicine that blocks the action of a hormone called aldosterone. Aldosterone tells the kidneys to hold on to salt and water, which raises blood pressure. By blocking aldosterone, spironolactone helps the body release more salt and water. Eplerenone works in a similar way. These medicines are used when blood pressure stays high even after trying three or more other medicines — this is called resistant hypertension. They are also used in people whose bodies make too much aldosterone. Spironolactone is often added as a fourth medicine. When you take it, your doctor will check your potassium levels and kidney function with blood tests.
Spironolactone is a mineralocorticoid receptor antagonist — it blocks the action of aldosterone, a hormone that causes the kidneys to retain sodium and water, raising blood pressure. The related drug eplerenone works the same way. These medications are used in resistant hypertension — blood pressure that stays high despite taking three or more other drugs — and in patients with hyperaldosteronism, a condition where the body produces too much aldosterone. Spironolactone is often added as a fourth medication when ACE inhibitors, ARBs, calcium channel blockers, and thiazides have not controlled blood pressure adequately. Regular monitoring of potassium and kidney function is standard with this drug class.
Spironolactone is a mineralocorticoid receptor antagonist — it blocks the action of aldosterone, a hormone that promotes sodium and water retention. Along with the related agent eplerenone, it is used in resistant hypertension (blood pressure not controlled despite three or more drugs) and in patients with hyperaldosteronism. Spironolactone is often added as a fourth agent when ACE inhibitors, ARBs, calcium channel blockers, and thiazides have not achieved adequate blood pressure control. Monitoring of potassium and kidney function is standard when using this class.
Spironolactone is a mineralocorticoid receptor antagonist (MRA) that competitively blocks aldosterone at its receptor, reducing renal sodium and water retention and thereby lowering blood pressure. The related agent eplerenone works through the same mechanism. This class is indicated in resistant hypertension — blood pressure uncontrolled on three or more antihypertensive agents — and in patients with primary hyperaldosteronism. Spironolactone is frequently added as a fourth antihypertensive agent after ACE inhibitors, ARBs, calcium channel blockers, and thiazides have failed to achieve adequate control. Monitoring of serum potassium and renal function is standard practice with MRA therapy.
Spironolactone is a competitive mineralocorticoid receptor antagonist (MRA) that blocks aldosterone binding at the mineralocorticoid receptor, reducing ENaC-mediated renal sodium reabsorption and attenuating potassium excretion. Eplerenone is a more selective MRA with a reduced off-target androgenic side-effect profile. Both agents are indicated in resistant hypertension — typically defined as blood pressure uncontrolled despite optimized triple therapy including a RAAS inhibitor, a dihydropyridine calcium channel blocker, and a thiazide-type diuretic — and in primary hyperaldosteronism. Spironolactone is typically deployed as a fourth-line antihypertensive agent; its efficacy in resistant hypertension is supported by the PATHWAY-2 trial. Routine surveillance of serum potassium and estimated GFR is mandatory given the risk of hyperkalemia and acute kidney injury, particularly in patients with baseline CKD or concurrent RAAS inhibition.
FormOral
FrequencyOnce daily
Approved1960–2002
OTCNo
From trialNo
04 / Novel therapies
Newer options worth knowing about.
Recently approved treatments or therapies that started in trials and are now part of care. Most of what's standard today went through this same path.
Entresto (sacubitril/valsartan)
sacubitril/valsartan
Novel · 2015
Entresto is a medicine that combines two drugs: sacubitril and valsartan. Sacubitril is a neprilysin inhibitor — it stops the body from breaking down natural proteins called natriuretic peptides, which help relax blood vessels and help the kidneys release more salt. Valsartan is an ARB (a blood pressure medicine that blocks the hormone angiotensin II). Entresto was approved in 2015 and is a standard treatment for a type of heart failure called heart failure with reduced ejection fraction — meaning the heart is not pumping as strongly as it should. A study called PARADIGM-HF showed it reduces the risk of death from heart failure. It also lowers blood pressure. Its role in treating high blood pressure without heart failure is still being studied. People who have both heart failure and high blood pressure may take it for both reasons.
Entresto combines two drugs: sacubitril — a neprilysin inhibitor that prevents the breakdown of natriuretic peptides, natural proteins that help relax blood vessels and promote sodium excretion through the kidneys — and valsartan, an ARB that blocks the blood-pressure-raising hormone angiotensin II. Approved in 2015, Entresto is an established standard treatment for heart failure with reduced ejection fraction, a condition where the heart does not pump strongly enough. The PARADIGM-HF trial showed significant mortality benefits. Entresto also lowers blood pressure, and its specific role in treating hypertension without heart failure is still being evaluated. Patients who have both conditions may be managed on Entresto as a treatment for both.
Entresto combines sacubitril — a neprilysin inhibitor that allows natriuretic peptides to promote vasodilation and sodium excretion — with valsartan, an ARB. Approved in 2015, it is established as a standard therapy in heart failure with reduced ejection fraction, where its blood pressure-lowering effects complement significant mortality benefits shown in the PARADIGM-HF trial. Its role specifically in hypertension without heart failure continues to be evaluated, but patients with both conditions may be managed on Entresto as a dual-purpose agent.
Entresto is a fixed-dose combination of sacubitril — a neprilysin inhibitor that prevents degradation of natriuretic peptides, thereby promoting vasodilation and natriuresis — and valsartan, an ARB. Approved in 2015, it is established as standard therapy in heart failure with reduced ejection fraction (HFrEF), where the PARADIGM-HF trial demonstrated significant mortality benefit. Its blood pressure-lowering effects complement its heart failure indication. The role of Entresto specifically for hypertension in the absence of heart failure continues to be evaluated; patients with both conditions may be managed on Entresto as a dual-purpose agent.
Entresto is a fixed-dose combination of sacubitril, a prodrug neprilysin inhibitor that prevents degradation of natriuretic peptides (ANP, BNP, CNP), thereby augmenting natriuretic peptide-mediated vasodilation, natriuresis, and suppression of the RAAS and sympathetic nervous system, and valsartan, an AT₁ receptor antagonist providing complementary RAAS blockade. Approved in 2015, Entresto is guideline-recommended standard-of-care for HFrEF following the PARADIGM-HF trial, which demonstrated a 20% relative risk reduction in the composite of cardiovascular death and heart failure hospitalization versus enalapril. Pleiotropic blood pressure-lowering effects accompany heart failure efficacy. The therapeutic role of sacubitril/valsartan specifically in hypertension without HFrEF remains under investigation; patients with comorbid hypertension and HFrEF may derive dual benefit from this agent.
FormOral
FrequencyTwice daily
FDA Approval2015
From trialYes
Azilsartan medoxomil
azilsartan medoxomil
Novel · 2011
Azilsartan medoxomil is a newer type of ARB — a medicine that blocks a hormone called angiotensin II, which raises blood pressure. It was approved in 2011. In studies that compared it directly to some older ARBs, including olmesartan and valsartan, azilsartan lowered blood pressure more at the approved doses. You take it once a day. It has the same uses and the same precautions as other ARBs. It is an option for people who have not reached their blood pressure goal with older ARBs. But long-term studies showing how well it prevents heart attacks and strokes — compared to older ARBs — are still being developed.
Azilsartan medoxomil is a newer ARB — a drug that blocks the receptor for angiotensin II, a hormone that raises blood pressure. Approved in 2011, it has shown greater blood pressure reduction than some older ARBs, including olmesartan and valsartan, in head-to-head comparisons at approved doses. It is taken once daily and carries the same class indications and precautions as other ARBs. It is an option for patients who have not achieved adequate blood pressure control with earlier ARBs, though long-term cardiovascular outcome data specific to azilsartan are still developing.
Azilsartan medoxomil is a newer angiotensin II receptor blocker approved in 2011. In head-to-head comparisons, it has demonstrated greater blood pressure reduction than some older ARBs, including olmesartan and valsartan, at approved doses. It is taken once daily and carries the same class indications and precautions as other ARBs. It represents an option for patients who have not achieved adequate control with earlier ARBs, though long-term cardiovascular outcome data specific to azilsartan are still developing.
Azilsartan medoxomil is a second-generation ARB approved in 2011. In direct comparative trials, it demonstrated greater blood pressure reduction than olmesartan and valsartan at approved doses. Administered once daily, it shares the class indications and precautions of other ARBs. It represents an option for patients with inadequate response to earlier ARBs, though long-term cardiovascular outcome data specific to azilsartan remain limited.
Azilsartan medoxomil is a second-generation ARB approved in 2011 that demonstrates higher AT₁ receptor binding affinity and more sustained receptor occupancy compared to earlier ARBs. In randomized head-to-head trials, azilsartan produced statistically greater 24-hour ambulatory blood pressure reductions than olmesartan and valsartan at respective approved doses. It is administered once daily and carries standard ARB class contraindications and precautions, including avoidance in pregnancy and caution with concurrent RAAS inhibition or hyperkalemia risk. It represents a pharmacologically differentiated option within the ARB class for patients with suboptimal response to first-generation ARBs, though definitive long-term cardiovascular outcome trial data specific to azilsartan are not yet available.
FormOral
FrequencyOnce daily
FDA Approval2011
From trialNo
Baxdrostat
baxdrostat
Novel · 2024
Baxdrostat is a new medicine approved in 2024. It lowers blood pressure in a specific way — it blocks the body from making a hormone called aldosterone. Aldosterone tells the kidneys to hold on to salt and water, which raises blood pressure. Baxdrostat works at the source by blocking the enzyme that makes aldosterone — this enzyme is called aldosterone synthase. It is meant for people whose blood pressure is hard to control even with other medicines. It is especially useful for people whose high blood pressure is caused by too much aldosterone. For some people, it may be an option instead of a medicine called spironolactone if spironolactone causes side effects. Clinical trial results showed that baxdrostat lowered blood pressure in people whose blood pressure was not controlled on existing medicines.
Baxdrostat is a highly selective aldosterone synthase inhibitor approved in 2024. Rather than blocking the receptor where aldosterone acts — as spironolactone does — baxdrostat reduces aldosterone production at the source by blocking the enzyme aldosterone synthase. It targets patients with uncontrolled or treatment-resistant hypertension, and it is particularly relevant for patients whose high blood pressure is driven by excess aldosterone activity. For patients who might otherwise use spironolactone but experience its side effects, baxdrostat may be an option. Its approval was based on clinical trial data showing blood pressure reductions in patients not controlled on existing drug regimens.
Baxdrostat is a highly selective aldosterone synthase inhibitor — it reduces aldosterone production at the source rather than blocking its receptor. Approved in 2024, it targets patients with uncontrolled or treatment-resistant hypertension. The mechanism is particularly relevant in patients whose hypertension is driven by excess aldosterone activity, including those who might otherwise require spironolactone but experience its side effects. Its approval followed clinical trial data demonstrating blood pressure reduction in patients not controlled on existing regimens.
Baxdrostat is a highly selective aldosterone synthase (CYP11B2) inhibitor approved in 2024 for uncontrolled or treatment-resistant hypertension. Unlike mineralocorticoid receptor antagonists such as spironolactone, baxdrostat reduces aldosterone production at the enzymatic level rather than blocking receptor action. It is particularly relevant in patients whose hypertension is mediated by excess aldosterone activity and may serve as an alternative for patients intolerant of spironolactone. Approval was supported by clinical trial data demonstrating blood pressure reduction in patients inadequately controlled on existing antihypertensive regimens.
Baxdrostat is a highly selective inhibitor of aldosterone synthase (CYP11B2), the terminal enzyme in adrenal aldosterone biosynthesis, approved in 2024 for uncontrolled and treatment-resistant hypertension. Its mechanism — direct suppression of aldosterone production rather than receptor antagonism — differentiates it from mineralocorticoid receptor antagonists such as spironolactone and eplerenone, and offers particular mechanistic relevance in aldosterone-mediated hypertension including primary hyperaldosteronism. Baxdrostat may represent an alternative for patients intolerant of spironolactone's off-target androgenic effects. FDA approval was supported by randomized clinical trial data demonstrating statistically significant blood pressure reductions in patients with inadequate control on background antihypertensive therapy, with CYP11B2 selectivity over the structurally homologous CYP11B1 (cortisol synthase) intended to mitigate adrenal insufficiency risk.
FormOral
FrequencyOnce daily
FDA Approval2024
From trialYes
A common misconception
Clinical trials aren't a last resort.
Some people think clinical trials are only for patients who have run out of other options. In high blood pressure research, that is rarely how it works. Most trials include patients who are already taking standard blood pressure medicines and then test a new treatment on top of that. People in trials are not asked to stop taking medicines that work. Safety boards watch the data throughout the study and can stop a trial early if a sign of serious harm appears.
A common misconception is that clinical trials are only for patients who have tried everything else and run out of options. In hypertension research, that is rarely the case. Most trials enroll patients who are already receiving standard antihypertensive therapy and test an investigational intervention added to or compared with that existing treatment. Participants are not asked to give up proven medications. Independent safety monitoring boards review data throughout the trial and have the authority to stop it early if a meaningful safety signal emerges.
A common misconception is that clinical trials are only for patients who have exhausted other options. In hypertension research, that is rarely how trials work. Most trials enroll patients who are receiving standard antihypertensive therapy and add or compare an investigational intervention on top of it. Participants are not asked to forgo proven treatment. Safety monitoring boards review data throughout and can halt a trial early if a meaningful harm signal emerges.
A common misconception is that clinical trials are reserved for patients who have exhausted all standard treatment options. In hypertension research, this is rarely how trials are structured. Most trials enroll patients already on standard antihypertensive therapy and evaluate an investigational intervention as an add-on or active comparator. Participants are not required to forgo established treatment. Data Safety Monitoring Boards (DSMBs) conduct ongoing safety reviews and are empowered to recommend early termination if a meaningful harm signal is identified.
A prevalent misconception is that participation in clinical trials is contingent on exhaustion of all available therapeutic options. In antihypertensive research, this is seldom the trial design paradigm. The predominant model enrolls patients on optimized background antihypertensive pharmacotherapy and evaluates an investigational agent as an add-on intervention or in active-comparator design — participants are not required to discontinue proven therapy. Independent Data Safety Monitoring Boards (DSMBs) conduct pre-specified interim analyses throughout the trial and retain authority to recommend early termination for harm under established stopping rules if a statistically or clinically meaningful safety signal emerges.
Baxdrostat, Entresto, and many of the medications now considered standard — including chlorthalidone in ALLHAT — were validated through the same trial process. The standard of care for hypertension today is the cumulative result of decades of rigorous clinical research.
05 / Landmark trials
The trials that built the treatments you have today.
Every medication on your standard-of-care list started as a clinical trial. This is the short history of how the field arrived at modern care — and where it's heading next.
Why this matters
Trials aren't separate from "real" medicine — they are how real medicine gets made.
Each study below changed the way doctors treat high blood pressure. Learning about these studies helps explain why certain medicines are preferred over others, why the target blood pressure number has changed over time, and why eating a certain diet is an official part of treatment — not just a suggestion.
Each of the trials below produced results that directly changed how hypertension is treated. Understanding this history helps explain why certain drugs are preferred over others, why blood pressure targets have shifted over time, and how dietary guidance became an official part of treatment — not just a general lifestyle suggestion.
Each trial below represents a study whose results directly altered how hypertension is treated. Understanding this lineage shows why certain drugs are preferred over others, why blood pressure targets have shifted over time, and how dietary guidance became an official component of treatment — not just a suggestion.
Each trial below produced results that directly altered clinical practice in hypertension management. Understanding this evidence base explains the rationale for preferred drug class selection, the evolution of blood pressure treatment targets over time, and the formal incorporation of dietary modification as a guideline-recommended therapeutic intervention rather than an informal lifestyle recommendation.
Each trial below represents a pivotal study whose results directly modified the standard of care for hypertension. Familiarity with this evidentiary lineage illuminates the mechanistic and outcome-based rationale underlying preferred first-line drug class designations, the historical and ongoing evolution of blood pressure treatment thresholds, and the evidence-graded transition of dietary modification — specifically the DASH eating pattern — from informal lifestyle counsel to a formally guideline-endorsed non-pharmacologic antihypertensive intervention.
2002
Phase 3Practice-changingRCT
ALLHAT: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial
This was the biggest study ever done on medicines that lower blood pressure. It found that an old, cheap water pill called chlorthalidone worked just as well as newer blood pressure medicines at stopping heart attacks and death from heart disease.
This was the largest blood pressure treatment study ever done. It found that chlorthalidone — an older, low-cost diuretic (water pill) — worked just as well as newer drug types at preventing heart attacks and cardiovascular death.
The largest antihypertensive outcomes trial ever conducted — it found that the older, inexpensive diuretic chlorthalidone was at least as effective as newer drug classes at preventing heart attack and cardiovascular death.
This landmark antihypertensive outcomes trial — the largest of its kind — demonstrated that chlorthalidone, an older thiazide-type diuretic, was at least as effective as newer drug classes in preventing myocardial infarction and cardiovascular mortality.
The largest antihypertensive outcomes trial conducted to date, this study established non-inferiority of chlorthalidone, a thiazide-type diuretic, relative to newer antihypertensive drug classes with respect to hard cardiovascular endpoints including myocardial infarction and cardiovascular death.
What it tested
ALLHAT enrolled more than 33,000 patients who had high blood pressure and were at high risk for heart problems. They were randomly assigned to take one of four medicines: chlorthalidone, amlodipine, lisinopril, or doxazosin. The main outcome researchers looked for was death from heart disease or a heart attack that did not cause death. The group taking doxazosin was stopped early because too many people in that group had heart failure. Results came out in 2002.
ALLHAT enrolled more than 33,000 high-risk patients with hypertension and randomly assigned them to treatment with one of four drugs: chlorthalidone, amlodipine, lisinopril, or doxazosin. The primary outcome was a combination of fatal coronary heart disease and nonfatal myocardial infarction — a heart attack that did not cause death. The doxazosin treatment group was stopped early because of an excess of heart failure events. Results were published in 2002.
ALLHAT enrolled more than 33,000 high-risk hypertensive patients and randomized them to treatment with chlorthalidone, amlodipine, lisinopril, or doxazosin. The primary endpoint was combined fatal coronary heart disease and nonfatal myocardial infarction. The doxazosin arm was stopped early due to excess heart failure events. Results were published in 2002.
ALLHAT enrolled more than 33,000 high-risk hypertensive patients and randomized them to chlorthalidone, amlodipine, lisinopril, or doxazosin. The primary endpoint was the combined incidence of fatal coronary heart disease and nonfatal myocardial infarction. The doxazosin arm was terminated early due to a significant excess of heart failure events. Results were published in 2002.
ALLHAT randomized more than 33,000 high-cardiovascular-risk hypertensive patients to four antihypertensive regimens: chlorthalidone (thiazide-like diuretic), amlodipine (dihydropyridine CCB), lisinopril (ACE inhibitor), and doxazosin (alpha-1 adrenergic antagonist). The primary composite endpoint was fatal coronary heart disease and nonfatal myocardial infarction. The doxazosin arm was halted early by the DSMB due to a statistically significant excess of heart failure hospitalizations relative to chlorthalidone. Primary results were published in JAMA in 2002.
What it changed
ALLHAT made thiazide-type diuretics — especially chlorthalidone — a key first-choice medicine for high blood pressure. It also showed that amlodipine and lisinopril work well as first-choice medicines in certain groups of patients. The current AHA and ACC guidelines for high blood pressure still reflect what ALLHAT found when choosing which medicines to recommend first.
ALLHAT established thiazide-type diuretics — specifically chlorthalidone — as a cornerstone of first-line hypertension treatment. It also confirmed amlodipine and lisinopril as effective first-line options in specific patient groups. Current AHA/ACC hypertension guidelines still reflect ALLHAT's findings in their recommendations for preferred drug classes.
ALLHAT cemented thiazide-type diuretics — specifically chlorthalidone — as a cornerstone of first-line antihypertensive therapy. It also supported amlodipine and lisinopril as effective first-line options in specific populations. Current AHA/ACC guidelines still reflect ALLHAT's findings in their preferred drug class recommendations.
ALLHAT established thiazide-type diuretics — specifically chlorthalidone — as a cornerstone of first-line antihypertensive therapy and validated amlodipine and lisinopril as effective first-line options in appropriate patient populations. Current AHA/ACC hypertension guidelines continue to reflect ALLHAT's findings in preferred drug class recommendations.
ALLHAT's primary results entrenched thiazide-type diuretics — specifically chlorthalidone — as a foundational first-line antihypertensive agent and validated the first-line status of amlodipine and lisinopril for appropriate patient populations. The trial's secondary findings, including chlorthalidone's superiority over lisinopril for stroke prevention in Black patients, informed population-specific prescribing nuances. Current AHA/ACC hypertension guidelines continue to incorporate ALLHAT-derived evidence in their preferred drug class designations.
SPRINT was a study that tested stricter blood pressure control. It showed that aiming for a top blood pressure number below 120 mmHg — instead of the usual goal of below 140 mmHg — lowered the chance of serious heart problems and death in adults at high risk who did not have diabetes.
SPRINT tested a more aggressive blood pressure target. It found that aiming for a systolic (top number) blood pressure below 120 mmHg — compared to the standard target of below 140 mmHg — cut the risk of major heart events and overall death in high-risk adults without diabetes.
SPRINT found that targeting a systolic blood pressure below 120 mmHg — more intensive than the then-standard target of below 140 mmHg — reduced major cardiovascular events and all-cause mortality in high-risk, non-diabetic adults.
SPRINT demonstrated that intensive systolic blood pressure control targeting below 120 mmHg, compared with standard treatment targeting below 140 mmHg, significantly reduced major adverse cardiovascular events (MACE) and all-cause mortality in high-risk, non-diabetic adults.
SPRINT demonstrated that an intensive systolic BP target of less than 120 mmHg, versus a standard target of less than 140 mmHg, significantly reduced the composite endpoint of major cardiovascular events and all-cause mortality in a high-risk, non-diabetic adult population, redefining evidence-based treatment thresholds.
What it tested
SPRINT enrolled about 9,300 adults aged 50 or older whose systolic blood pressure — the top number — was between 130 and 180 mmHg and who had a high risk of heart problems but did not have diabetes. They were randomly assigned to aim for a systolic blood pressure below 120 mmHg or below 140 mmHg. The main outcome was a combination of heart attack, a heart emergency called acute coronary syndrome, stroke, heart failure, and death from heart disease. The study was stopped early in 2015 when early results showed the lower target was clearly better.
SPRINT enrolled approximately 9,300 adults aged 50 or older with systolic blood pressure between 130 and 180 mmHg and elevated cardiovascular risk but without diabetes. Participants were randomly assigned to an intensive systolic target of less than 120 mmHg or a standard target of less than 140 mmHg. The main composite outcome included myocardial infarction, acute coronary syndrome, stroke, heart failure, and cardiovascular death. The trial was stopped early in 2015 when interim results showed significant benefit in the intensive target group.
SPRINT enrolled approximately 9,300 adults aged 50 or older with systolic blood pressure between 130 and 180 mmHg and elevated cardiovascular risk but without diabetes. Participants were randomized to an intensive systolic target of less than 120 mmHg versus a standard target of less than 140 mmHg. The primary composite endpoint included myocardial infarction, acute coronary syndrome, stroke, heart failure, and cardiovascular death. The trial was stopped early in 2015 when interim results showed significant benefit in the intensive arm.
SPRINT enrolled approximately 9,300 adults aged 50 or older with systolic blood pressure between 130 and 180 mmHg and elevated cardiovascular risk but without diabetes. Participants were randomized to an intensive systolic target of less than 120 mmHg versus a standard target of less than 140 mmHg. The primary composite endpoint included myocardial infarction, acute coronary syndrome, stroke, heart failure, and cardiovascular death. The trial was stopped early in 2015 based on interim data showing significant benefit in the intensive arm.
SPRINT enrolled approximately 9,300 adults aged 50 or older with systolic blood pressure between 130 and 180 mmHg, elevated ASCVD risk, and without diabetes mellitus or prior stroke. Participants were randomized to an intensive systolic target of less than 120 mmHg versus a standard target of less than 140 mmHg. The primary composite endpoint comprised myocardial infarction, acute coronary syndrome, stroke, acute decompensated heart failure, and cardiovascular death. An independent DSMB recommended early termination in 2015 after pre-specified interim analyses demonstrated statistically significant and clinically meaningful benefit in the intensive-treatment arm, with a 25% relative risk reduction in the primary endpoint.
What it changed
SPRINT changed blood pressure guidelines. It helped move the target to below 130/80 mmHg in the 2017 ACC/AHA guidelines — made by heart doctor groups. It also helped shape the 2025 AHA/ACC guidelines. The study showed that lower blood pressure goals can help high-risk patients chosen carefully, but the benefit was not the same for every type of patient. Doctors need to look at each person on their own.
SPRINT directly led to the 2017 ACC/AHA guideline change that set a new blood pressure target of less than 130/80 mmHg for most people, and it also helped shape the 2025 AHA/ACC guidelines. The trial showed that more aggressive blood pressure lowering can reduce serious events in carefully selected high-risk patients — but it also made clear that this approach needs to be tailored to each person, since the benefit was not the same for all groups.
SPRINT directly influenced the 2017 ACC/AHA guideline shift toward a universal blood pressure target of less than 130/80 mmHg and contributed to the subsequent 2025 AHA/ACC guideline development. The trial established that more aggressive blood pressure lowering reduces events in carefully selected high-risk patients — but also highlighted that intensive targets require individualized assessment, as the benefit was not uniform across all subgroups.
SPRINT directly informed the 2017 ACC/AHA guideline revision that established a universal blood pressure target of less than 130/80 mmHg and contributed to the subsequent 2025 AHA/ACC guideline development. The trial supported more aggressive BP lowering in carefully selected high-risk patients, while also demonstrating that intensive targets require individualized clinical assessment, as benefits were not uniformly distributed across all patient subgroups.
SPRINT served as a pivotal evidence base for the 2017 ACC/AHA hypertension guideline's adoption of a universal BP target of less than 130/80 mmHg and continued to inform the 2025 AHA/ACC guideline development. The trial substantiated the cardiovascular benefit of intensive BP reduction in carefully phenotyped high-risk populations; however, heterogeneity of treatment effect across subgroups underscored the necessity of individualized risk–benefit assessment when applying intensive targets in clinical practice.
Published source available on request
1997
Phase 3RCTLifestyle
DASH: Dietary Approaches to Stop Hypertension Trial
DASH was a study about eating habits and blood pressure. It showed that eating more fruits, vegetables, and low-fat dairy foods — and eating less salt and saturated fat (the kind of fat found in butter and fatty meat) — can clearly lower blood pressure. This worked for people with high blood pressure and for people with normal blood pressure.
DASH showed that a specific eating plan — one that emphasizes fruits, vegetables, and low-fat dairy while cutting back on sodium and saturated fat — can significantly lower blood pressure, both in people who already have hypertension (high blood pressure) and those who don't.
DASH demonstrated that a specific dietary pattern — emphasizing fruits, vegetables, and low-fat dairy while limiting sodium and saturated fat — significantly lowers blood pressure in adults with and without hypertension.
DASH established that a dietary pattern emphasizing fruits, vegetables, and low-fat dairy products while restricting sodium and saturated fat intake produces significant blood pressure reductions in adults both with and without hypertension.
DASH established that a structured dietary intervention emphasizing fruits, vegetables, and low-fat dairy with concomitant restriction of sodium and saturated fat yielded clinically significant reductions in blood pressure across participants with and without baseline hypertension, providing level-I dietary evidence for antihypertensive management.
What it tested
The DASH trial enrolled 459 adults whose systolic blood pressure — the top number — was below 160 mmHg and whose diastolic pressure — the bottom number — was between 80 and 95 mmHg. They were randomly assigned to one of three diets: a typical American diet, a diet with more fruits and vegetables, or the full DASH diet combining all the changes. All participants kept their salt intake and body weight the same throughout the 8-week study. Results were published in 1997.
The DASH trial enrolled 459 adults with systolic blood pressure below 160 mmHg and diastolic pressure — the bottom number — between 80 and 95 mmHg. Participants were randomly assigned to one of three diets: a control diet typical of U.S. eating patterns, a diet rich in fruits and vegetables, or the full DASH combination diet. Sodium intake and body weight were kept stable throughout the 8-week study period. Results were published in 1997.
The DASH trial enrolled 459 adults with systolic blood pressure under 160 mmHg and diastolic pressure between 80 and 95 mmHg. Participants were randomized to one of three diets: a control diet typical of U.S. eating patterns, a diet rich in fruits and vegetables, or the full DASH combination diet. All participants maintained stable sodium intake and body weight throughout the 8-week feeding period. Results were published in 1997.
The DASH trial enrolled 459 adults with systolic blood pressure below 160 mmHg and diastolic pressure between 80 and 95 mmHg and randomized them to one of three dietary regimens: a control diet reflecting typical U.S. intake, a fruits-and-vegetables-enriched diet, or the full DASH combination diet. Sodium intake and body weight were held constant throughout the 8-week controlled feeding period. Results were published in 1997.
The DASH trial enrolled 459 adults with systolic blood pressure below 160 mmHg and diastolic blood pressure between 80 and 95 mmHg in a randomized controlled feeding trial comparing three dietary regimens: a control diet mirroring average U.S. macronutrient and micronutrient intake, a diet enriched in fruits and vegetables, and the full DASH combination diet — characterized by high fruit, vegetable, and low-fat dairy intake with reduced total fat, saturated fat, and red meat. Sodium intake and body weight were rigorously maintained constant across all arms throughout the 8-week feeding period to isolate dietary pattern effects. Results were published in the New England Journal of Medicine in 1997.
What it changed
The DASH trial proved that changing your diet is a real medical treatment for high blood pressure — not just general advice. The DASH eating plan is now officially recommended in AHA and ACC guidelines as a key non-medicine strategy. For people with stage 1 high blood pressure, following the DASH diet can lower blood pressure by about as much as taking a single blood pressure medicine.
DASH established dietary modification as a clinically meaningful, evidence-based treatment — not just a lifestyle suggestion. The DASH eating pattern is now explicitly recommended in AHA/ACC hypertension guidelines as a primary non-pharmacologic strategy. For patients with stage 1 hypertension, the blood pressure reduction from the DASH diet can be comparable to that of a single antihypertensive medication.
DASH established dietary modification as a clinically meaningful, evidence-based intervention — not a lifestyle suggestion. The DASH eating pattern is now explicitly recommended in AHA/ACC hypertension guidelines as a primary non-pharmacologic strategy. For patients with stage 1 hypertension, the blood pressure reduction from the DASH diet can be comparable to that of a single antihypertensive medication.
DASH established dietary modification as a clinically significant, evidence-based antihypertensive intervention rather than an informal lifestyle recommendation. The DASH eating pattern is formally recommended in AHA/ACC hypertension guidelines as a primary non-pharmacologic strategy. In patients with stage 1 hypertension, the blood pressure reduction achievable with the DASH diet is comparable to that of a single antihypertensive agent.
DASH provided Level A randomized controlled evidence that a structured dietary pattern constitutes a clinically meaningful antihypertensive intervention independent of pharmacotherapy, with the DASH diet producing systolic blood pressure reductions approaching those achievable with a single antihypertensive agent in stage 1 hypertension. These findings elevated dietary modification from general health counsel to a formally guideline-endorsed, evidence-graded non-pharmacologic antihypertensive strategy in AHA/ACC guidelines, where the DASH eating pattern is now a primary recommendation in the non-pharmacologic management algorithm.
Published source available on request
2003
Phase 3RCTACE inhibitor vs CCB
ASCOT-BPLA: Anglo-Scandinavian Cardiac Outcomes Trial — Blood Pressure Lowering Arm
ASCOT-BPLA compared two ways of treating high blood pressure. One group started with a medicine called amlodipine, and doctors could add perindopril if needed. The other group started with atenolol, and doctors could add bendroflumethiazide if needed. Both groups ended up with similar blood pressure levels. Even so, the amlodipine group had far fewer serious heart problems.
ASCOT-BPLA compared two blood pressure treatment plans. One started with amlodipine (adding perindopril if needed), and the other started with atenolol (adding bendroflumethiazide if needed). Even though both plans lowered blood pressure by about the same amount, the amlodipine-based plan led to significantly fewer cardiovascular events.
ASCOT-BPLA found that a regimen starting with amlodipine (with perindopril added as needed) reduced cardiovascular events significantly more than a regimen starting with atenolol (with bendroflumethiazide added as needed), despite similar blood pressure reductions between the two arms.
ASCOT-BPLA demonstrated that an amlodipine-based regimen (with perindopril added as needed) significantly reduced cardiovascular events compared with an atenolol-based regimen (with bendroflumethiazide added as needed), despite achieving similar blood pressure reductions across both treatment arms — suggesting that drug class effects beyond blood pressure lowering influence outcomes.
ASCOT-BPLA showed that an amlodipine/perindopril-based antihypertensive regimen conferred significantly greater cardiovascular event reduction than an atenolol/bendroflumethiazide-based regimen despite comparable achieved blood pressure levels across arms, implicating pleiotropic and class-specific effects — rather than BP lowering alone — as determinants of cardiovascular outcomes in hypertension management.
What it tested
ASCOT-BPLA enrolled 19,257 patients with high blood pressure who had at least three other risk factors for heart disease. They were randomly assigned to start treatment with either amlodipine or atenolol. The main outcome was a heart attack that did not cause death or death from heart disease. The group treated with atenolol was stopped early in 2005 because their outcomes were significantly worse — even though both groups reached similar blood pressure levels.
ASCOT-BPLA enrolled 19,257 patients with hypertension and at least three cardiovascular risk factors. They were randomized to an amlodipine-based or an atenolol-based treatment regimen. The primary endpoint was nonfatal myocardial infarction — a heart attack that did not cause death — and fatal coronary heart disease. The atenolol-based arm was stopped early in 2005 because outcomes were significantly worse, despite similar blood pressure levels achieved in both groups.
ASCOT-BPLA enrolled 19,257 hypertensive patients with at least three cardiovascular risk factors and randomized them to an amlodipine-based regimen or an atenolol-based regimen. The primary endpoint was nonfatal myocardial infarction and fatal coronary heart disease. The atenolol-based arm was stopped early in 2005 due to significantly worse outcomes despite similar achieved blood pressure levels in both groups.
ASCOT-BPLA enrolled 19,257 hypertensive patients with at least three cardiovascular risk factors and randomized them to an amlodipine-based or atenolol-based regimen. The primary endpoint was nonfatal myocardial infarction and fatal coronary heart disease. The atenolol-based arm was terminated early in 2005 due to significantly worse outcomes despite similar achieved blood pressure levels in both treatment groups.
ASCOT-BPLA randomized 19,257 hypertensive patients with at least three cardiovascular risk factors to an amlodipine-based regimen (with perindopril added as needed) or an atenolol-based regimen (with bendroflumethiazide-K added as needed). The primary endpoint was nonfatal myocardial infarction and fatal coronary heart disease. The atenolol-based arm was halted early by the DSMB in 2005 following demonstration of significantly worse cardiovascular outcomes relative to the amlodipine arm, despite near-equivalent achieved blood pressure reductions — implicating drug class-specific pleiotropic effects as determinants of outcome differences.
What it changed
ASCOT-BPLA played a big role in moving doctors away from using beta-blockers like atenolol as the first medicine for most people with high blood pressure. The finding that the type of medicine mattered — not just the blood pressure number it reached — showed how important it is to use medicines with proven outcomes data. The trial helped establish calcium channel blockers and ACE inhibitors as preferred first-choice medicines in current guidelines.
ASCOT-BPLA contributed substantially to the shift away from beta-blockers as the preferred first-line treatment for uncomplicated hypertension. The finding that drug class mattered independently of achieved blood pressure reinforced the importance of choosing agents with proven cardiovascular outcome data. The trial supported the preferred first-line status of calcium channel blockers and ACE inhibitors in current guidelines.
ASCOT-BPLA contributed substantially to the shift away from beta-blockers as preferred first-line agents for uncomplicated hypertension. The finding that drug class mattered beyond blood pressure numbers reinforced the importance of selecting agents with proven outcome data. The trial supported the preferred first-line status of calcium channel blockers and ACE inhibitors in current guidelines.
ASCOT-BPLA substantially contributed to the downgrading of beta-blockers from preferred first-line status for uncomplicated hypertension. The demonstration that drug class influenced outcomes beyond blood pressure reduction reinforced the clinical relevance of selecting agents with robust cardiovascular outcome data. The trial supported the preferred first-line positions of calcium channel blockers and ACE inhibitors in current AHA/ACC guidelines.
ASCOT-BPLA provided pivotal evidence supporting the demotion of beta-blockers — particularly atenolol — from preferred first-line antihypertensive status for uncomplicated hypertension in major international guidelines. The demonstration that cardiovascular outcome differences emerged despite comparable blood pressure control strongly implicated drug class-specific pleiotropic mechanisms — including differential effects on central aortic pressure, insulin sensitivity, and sympathetic activation — as determinants of outcome divergence. The trial substantiated the guideline preference for calcium channel blockers and ACE inhibitors as first-line antihypertensive agents and remains a key reference for drug class selection in uncomplicated hypertension.
Published source available on request
2010
Phase 3RCTARBRenal protection
ONTARGET: Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial
ONTARGET compared two types of blood pressure medicines in people at high risk for heart problems. One type is called an ARB — the study used telmisartan. The other type is called an ACE inhibitor — the study used ramipril. The study found they worked equally well. It also found that taking both medicines together did not help more than taking just one, and it caused more side effects.
ONTARGET compared two blood pressure drug types in high-risk patients: the ARB telmisartan and the ACE inhibitor ramipril. It found both were equally effective at preventing cardiovascular events. Importantly, combining both drug types did not improve outcomes and actually led to more side effects.
ONTARGET showed that the ARB telmisartan was as effective as the ACE inhibitor ramipril for cardiovascular outcomes in high-risk patients — and that combining both drug classes did not improve outcomes while increasing adverse effects.
ONTARGET demonstrated that the ARB telmisartan was non-inferior to the ACE inhibitor ramipril for cardiovascular outcomes in high-risk patients, while dual blockade of the renin-angiotensin system — combining both agents — failed to improve outcomes and was associated with increased adverse effects, including hypotension and renal impairment.
ONTARGET established non-inferiority of the ARB telmisartan versus the ACE inhibitor ramipril on composite cardiovascular endpoints in a high-risk population, while demonstrating that dual renin-angiotensin-aldosterone system (RAAS) blockade with combined telmisartan and ramipril conferred no incremental cardiovascular benefit and significantly increased rates of adverse effects — including hypotension, syncope, and renal dysfunction — precluding routine use of combined ACE inhibitor/ARB therapy.
What it tested
ONTARGET enrolled 25,620 patients who had a high risk of heart problems — either because they had established atherosclerosis (narrowing and hardening of arteries from plaque buildup) or because they had diabetes with organ damage. They were randomly assigned to take ramipril alone, telmisartan alone, or both medicines together. The main outcome was a combination of death from heart disease, heart attack, stroke, and hospital admission for heart failure. Main results were published in 2008, with follow-up analyses through 2010.
ONTARGET enrolled 25,620 patients with established atherosclerotic disease or diabetes with end-organ damage — meaning heart, kidney, or other organ damage caused by diabetes. Participants were randomly assigned to ramipril, telmisartan, or the combination of both. The primary outcome was a composite of cardiovascular death, myocardial infarction, stroke, and hospitalization for heart failure. Results were published in 2008, with follow-up analyses through 2010.
ONTARGET enrolled 25,620 high-cardiovascular-risk patients with established atherosclerotic disease or diabetes with end-organ damage, and randomized them to ramipril, telmisartan, or the combination of both. The primary composite endpoint included cardiovascular death, myocardial infarction, stroke, and hospitalization for heart failure. Results were published in 2008 and follow-up analyses extended through 2010.
ONTARGET enrolled 25,620 high-cardiovascular-risk patients with established atherosclerotic disease or diabetes with end-organ damage and randomized them to ramipril, telmisartan, or the combination of both. The primary composite endpoint included cardiovascular death, myocardial infarction, stroke, and hospitalization for heart failure. Results were published in 2008 and follow-up analyses extended through 2010.
ONTARGET enrolled 25,620 patients with established atherosclerotic cardiovascular disease or diabetes mellitus with end-organ damage and randomized them in a three-arm design to ramipril 10 mg daily, telmisartan 80 mg daily, or the combination of ramipril plus telmisartan. The primary composite endpoint comprised cardiovascular death, myocardial infarction, stroke, and hospitalization for heart failure. Primary results were published in the New England Journal of Medicine in 2008, with extended follow-up analyses published through 2010.
What it changed
ONTARGET established ARBs as an accepted alternative to ACE inhibitors for high-risk heart patients — something that had been assumed but not proven in a large study until then. More importantly, it showed clearly that taking both types of medicines together — an ACE inhibitor and an ARB — did not improve heart outcomes and actually caused more kidney failure and low blood pressure. This practice had been common before the trial. Current guidelines recommend against combining them.
ONTARGET established ARBs as a guideline-supported alternative to ACE inhibitors in high-risk cardiovascular patients, confirming the class equivalence that had previously been assumed. More critically, the trial showed that combining an ACE inhibitor with an ARB — a practice that was common at the time — did not improve cardiovascular outcomes and increased rates of kidney failure and low blood pressure. Current guidelines recommend against that combination.
ONTARGET established ARBs as a guideline-supported alternative to ACE inhibitors in high-risk cardiovascular patients, validating the class equivalence that had been inferred but not directly tested in large outcomes data. Critically, the trial provided strong evidence against combining an ACE inhibitor with an ARB — a practice that was common at the time — showing that dual blockade increased kidney failure and hypotension without cardiovascular benefit. Current guidelines recommend against that combination.
ONTARGET established ARBs as a guideline-supported alternative to ACE inhibitors in high-risk cardiovascular patients, confirming class equivalence on major outcomes. Critically, the combination arm demonstrated that dual RAAS blockade with an ACE inhibitor and ARB provided no cardiovascular benefit while significantly increasing rates of renal failure and hypotension — a then-common prescribing practice. Current guidelines explicitly recommend against combining an ACE inhibitor with an ARB.
ONTARGET established guideline-validated class equivalence between ARBs and ACE inhibitors for major cardiovascular endpoints in high-risk patients, confirming the clinical inference of RAAS inhibitor interchangeability with prospective outcomes data. The trial's most consequential finding was the definitive demonstration that dual RAAS blockade — concurrent ACE inhibitor plus ARB therapy, which was prevalent at the time — conferred no reduction in the primary cardiovascular composite endpoint while significantly increasing rates of hypotension, syncope, renal impairment, and dialysis-requiring acute kidney injury. These data prompted guideline-level recommendations against dual RAAS blockade, which persist in current AHA/ACC guidance.
Published source available on request
2025
GuidelinePractice-changingAHA/ACC
2025 AHA/ACC Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults
The 2025 AHA/ACC guideline is the most up-to-date official guide on blood pressure for adults. It tells doctors how to sort blood pressure into groups, when to start treatment, and which medicines to use. It uses the newest research, including the SPRINT study and recent medicine data, and updates the rules that were set in 2017.
The 2025 AHA/ACC guideline is the current official standard for managing blood pressure in adults. It covers how to classify blood pressure, when to treat it, and which medications to choose. It reflects the latest evidence — including findings from SPRINT and newer drug studies — and updates the previous 2017 version.
The 2025 AHA/ACC guideline is the current authoritative framework for blood pressure classification, treatment thresholds, and medication selection in adults — incorporating evidence accumulated since the 2017 update, including SPRINT and newer drug data.
The 2025 AHA/ACC guideline represents the current authoritative clinical practice framework for blood pressure classification, treatment thresholds, and pharmacologic selection in adults, integrating evidence accumulated since the 2017 update — including SPRINT trial data and emerging antihypertensive drug evidence.
The 2025 AHA/ACC hypertension guideline constitutes the current authoritative evidence-based clinical practice framework, operationalizing blood pressure staging, risk-stratified treatment thresholds, and preferred pharmacologic agents across defined patient populations. It incorporates a systematic synthesis of data accrued since the 2017 iteration, including SPRINT outcome data and contemporary antihypertensive drug class evidence.
What it tested
This guideline was made by two large heart health groups: the American Heart Association and the American College of Cardiology. They looked at many studies — including carefully controlled trials, large reviews of many studies, and studies that tracked patients over time — and put all that information together. The guideline explains what counts as high blood pressure, sets blood pressure goals for different types of patients, and says which medicines work best in different situations.
This is a full clinical practice guideline created by the American Heart Association and the American College of Cardiology. The two organizations reviewed evidence from randomized controlled trials (studies where patients are randomly assigned to treatments), meta-analyses (large studies that combine results from many trials), and observational studies (studies that track patients over time). The guideline defines the stages of hypertension, sets blood pressure goals for different patient groups, and recommends the best drug choices for specific medical situations.
This is a comprehensive evidence-based clinical practice guideline developed by the American Heart Association and American College of Cardiology, synthesizing data from randomized controlled trials, meta-analyses, and observational studies. It defines hypertension stages, establishes BP targets for various patient populations, and recommends preferred drug classes for specific clinical contexts.
This comprehensive evidence-based clinical practice guideline was jointly developed by the American Heart Association and American College of Cardiology, synthesizing data from randomized controlled trials, meta-analyses, and observational studies. It establishes hypertension staging criteria, delineates blood pressure targets across diverse patient populations, and provides preferred pharmacologic recommendations for specific clinical contexts.
This comprehensive evidence-based clinical practice guideline, developed through a joint American Heart Association/American College of Cardiology methodology, synthesizes data from randomized controlled trials, meta-analyses, and observational cohorts to operationalize hypertension staging, risk-stratified BP targets across heterogeneous patient populations, and preferred drug-class selection for defined clinical indications and comorbidity profiles.
What it changed
The 2025 guideline is the current standard that all high blood pressure care is measured against. It sets the numbers your doctor uses to decide when to start medicine, which medicine to start with, and how aggressively to work toward your blood pressure goal. Knowing that your care follows a trusted, evidence-based plan — rather than just one doctor's habit — can be reassuring when you see different doctors who give slightly different recommendations.
The 2025 guideline is the current standard against which all hypertension management is measured. It defines the treatment thresholds your clinician uses to decide when to start medication, which drug class to start with, and how aggressively to target your blood pressure goal. For patients, knowing that your care is guided by a structured, evidence-based framework — rather than individual clinical habit — can be reassuring when different clinicians give slightly different recommendations.
The 2025 guideline represents the current standard against which all hypertension management is benchmarked. It defines the treatment thresholds your clinician uses to decide when to start medication, which drug class to start with, and how aggressively to pursue your blood pressure goal. For patients, understanding that your care follows a structured evidence-based framework — rather than individual clinical habit — can be reassuring when different clinicians give slightly different recommendations.
The 2025 AHA/ACC guideline represents the current benchmark against which all hypertension management is evaluated. It defines the treatment thresholds, preferred drug classes, and blood pressure targets that guide clinical decision-making. For patients, understanding that their care follows a structured, evidence-based framework provides context for minor variation in recommendations across different clinicians.
The 2025 AHA/ACC hypertension guideline constitutes the current benchmark against which antihypertensive management is clinically and academically evaluated. It defines pharmacologic initiation thresholds, target blood pressures stratified by risk and comorbidity, and evidence-graded drug class preferences that govern contemporary prescribing decisions. From a patient-facing perspective, awareness that individualized clinical recommendations are derived from a structured, continuously updated evidence-based framework provides context for apparent inter-clinician variation in management recommendations, which typically reflects individualized risk-benefit application of guideline principles rather than idiosyncratic practice.
Published source available on request
06 / Support & resources
People and places that get it.
Patient communities, foundations, and clinical centers that focus on this condition. Save any of these to keep them on your dashboard.
Patient Foundation
American Heart Association — High Blood Pressure
Comprehensive patient education on hypertension causes, diagnosis, treatment, and heart-healthy lifestyle guidance.
This page is educational, not medical advice. Talk with your care team about decisions that apply to you. If something feels urgent — such as a sudden severe headache, chest pain, vision changes, or very high blood pressure reading — contact your doctor or call your local emergency number.
